Understanding how certain cancer drugs affect the heart to improve treatment outcomes.
Defining kinase interaction pathways to enhance anti-cancer efficacy and minimize associated morbidities of kinase inhibitor drugs.
This study is looking at how certain cancer drugs called Tyrosine Kinase Inhibitors (TKIs) affect heart health, with the goal of finding ways to make these treatments safer for cancer patients while still being effective.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project ID | NIH-10896175 on NIH RePORTER |
What this research studies
This research investigates the effects of Tyrosine Kinase Inhibitors (TKIs), which are commonly used cancer treatments, on cardiovascular health. It aims to identify the specific kinase interactions that lead to both the anti-cancer effects and the cardiovascular side effects of these drugs. By using advanced pharmacological and genetic techniques, the study seeks to map out the signaling networks involved in these processes, potentially leading to safer treatment options for cancer patients. The findings could help in developing new drug analogues that minimize harmful side effects while maintaining efficacy against cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients, particularly those with Chronic Myeloid Leukemia (CML), who are being treated with Tyrosine Kinase Inhibitors.
Not a fit: Patients who are not undergoing treatment with Tyrosine Kinase Inhibitors or those with conditions unrelated to the cardiovascular effects of cancer treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved cancer treatments that reduce harmful cardiovascular side effects, enhancing the quality of life for patients.
How similar studies have performed: Previous research has shown promise in understanding kinase interactions and their effects on cancer treatment, suggesting that this approach could yield valuable insights.
Where this research is happening
Stanford, United States
- Stanford University — Stanford, United States (Active)
Researchers
- Principal investigator: Hnatiuk Hnatiuk, Anna Pavlovna — Stanford University
- Study coordinator: Hnatiuk Hnatiuk, Anna Pavlovna
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.